Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of cetuximab plus temozolomide with concomitant radiotherapy in newly diagnosed unresectable or incompletely resected supratentorial malignant glioma
2006-001881-18Phase 2Active
- Sponsor
- Fundación de la Universidad Autónoma de Madrid
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and temozolomide in malignant glioma, sponsored by Fundación de la Universidad Autónoma de Madrid. Primary endpoints: Objective response rate after induction therapy and Objective response rate after induction therapy followed by concomitant radiotherapy. Started Jun 2006; status: active.
02
Drugs
cetuximabtemozolomide
03
Conditions
malignant glioma
Beyond the preview
Go deeper on 2006-001881-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001881-18.